Table 1.
Baseline tumor PD-L1 expression and HPV status.
| Patients, n (%) | Nivolumab (n = 240) | IC (n = 121) |
|---|---|---|
| Tumor PD-L1 expression | 40 (33.1) | |
| Non-expressors (< 1%) | 76 (31.7) | 40 (33.1) |
| Expressors (≥1%) | 96 (40.0) | 63 (52.1) |
| Not quantifiable | 68 (28.3) | 18 (14.9) |
| Tumor HPV status | ||
| Positive | 64 (26.7) | 29 (24.0) |
| Negative | 56 (23.3) | 37 (30.6) |
| Unknown/not reported | 120 (50.0) | 55 (45.5) |
IC, investigator’s choice; HPV, human papillomavirus; PD-L1, programmed death ligand 1.